Investor Relations

Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.

Events

Upcoming Events

There are currently no upcoming events announced.

Past Events

Select Year:
May 15, 2024 9:00 AM ETHoth Therapeutics to Attend EF Hutton Annual Global Conference
Hoth Therapeutics to Attend EF Hutton Annual Global Conference. Please see https://efhutton.com/conference/ for additional information.


You are about to review presentations, reports and/or filings of Hoth Therapeutics, Inc., that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Hoth Therapeutics, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by Hoth Therapeutics, Inc.

February 26, 2024 9:00 AM ETHoth Therapeutics to Attend BIO CEO and Investor Conference
Hoth Therapeutics to Attend BIO CEO and Investor Conference in New York. Please visit https://bcic.bio.org for additional information.


You are about to review presentations, reports and/or filings of Hoth Therapeutics, Inc., that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Hoth Therapeutics, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by Hoth Therapeutics, Inc.

November 21, 2022 1:30 PM ETClinical Trials Nexus. Panel Discussion – New Times, New Solutions: Key Challenges for Small Sponsors.
Dr. Stefanie Johns will be a panelist. Dr. Stefanie Johns will be a panelist. Panel Discussion – New Times, New Solutions: Key Challenges for Small Sponsors. Please visit: https://procurementdirect.co.uk/ctneast/


You are about to review presentations, reports and/or filings of Hoth Therapeutics, Inc., that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Hoth Therapeutics, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by Hoth Therapeutics, Inc.

November 21, 2022 11:30 AM ETClinical Trials Nexus. Panel Discussion – Early Phase Engagement Patterns Between Pharma and CRO.
Dr. Stefanie Johns will be a panelist. Dr. Stefanie Johns will be a panelist. Panel Discussion – Early Phase Engagement Patterns Between Pharma and CRO. Please visit: https://procurementdirect.co.uk/ctneast/


You are about to review presentations, reports and/or filings of Hoth Therapeutics, Inc., that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Hoth Therapeutics, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by Hoth Therapeutics, Inc.

July 31, 2022 9:00 AM ETAlzheimer’s Association International Conference
Dr. Stefanie Johns, Chief Scientific Officer and Dr. Carla Yuede, Scientific Advisory Board member will be presenting results from cognitive and behavioral studies currently underway with HT-ALZ using an APP/PS1 mouse model. For more information or to register please visit the conference website: https://aaic.alz.org/registration.asp


You are about to review presentations, reports and/or filings of Hoth Therapeutics, Inc., that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Hoth Therapeutics, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by Hoth Therapeutics, Inc.

June 13, 2022 9:00 AM ETBIO International Convention
Dr. Stefanie Johns, Chief Scientific Officer, will be presenting. For more information or to register please visit the conference website: https://www.bio.org/events/bio-international-convention.


You are about to review presentations, reports and/or filings of Hoth Therapeutics, Inc., that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Hoth Therapeutics, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by Hoth Therapeutics, Inc.

September 30, 2021 3:00 PM ETBenzinga HEALTHCARE SMALL CAP CONFERENCE
Robb Knie, CEO, will be presenting at the Benzinga Healthcare Small Cap Conference. For more information and to register, please visit the conference website: https://www.benzinga.com/events/small-cap/healthcare/


You are about to review presentations, reports and/or filings of Hoth Therapeutics, Inc., that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Hoth Therapeutics, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by Hoth Therapeutics, Inc.

September 13, 2021 9:00 AM ETH.C. Wainwright 23rd Annual Global Investment Conference (Virtual Conference)
Robb Knie, CEO, will be presenting at the virtual conference and the pre-recorded presentation that is available on-demand, starting on September 13 at 7:00 A.M. (ET).  Once the session becomes available on-demand, attendees can submit their Q & A's, they will appear on the "speaker dashboard" page for the Company’s review. Please visit: https://hcwevents.com/annualconference/ to register and view our company presentation.


You are about to review presentations, reports and/or filings of Hoth Therapeutics, Inc., that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Hoth Therapeutics, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by Hoth Therapeutics, Inc.

June 4, 2021 9:00 AM ET2021 ASCO Annual Meeting
Attendees of the American will be able to visit the Hoth Therapeutics booth virtually starting May 24th through July 6, 2021. Hoth Therapeutics is dedicated to helping address unmet medical needs and improve the quality of life for patients living with rare cancers through the development of its assets, HT-KIT and HT-001.
Listen to the Webcast


You are about to review presentations, reports and/or filings of Hoth Therapeutics, Inc., that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Hoth Therapeutics, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by Hoth Therapeutics, Inc.

June 3, 2021 9:00 AM ETHoth Therapeutics Presents HT-KIT Oncology Treatment
HT-KIT is an mRNA frame-shifting therapeutic designed to specifically target the receptor tyrosine kinase KIT, which is required for the proliferation, survival and differentiation of bone marrow-derived hematopoietic stem cells. Mutations in the KIT pathway have been associated with several human cancers, such as mast cell-derived cancers, systemic mastocytosis with associated hematologic neoplasm, or mast cell leukemia, gastrointestinal stromal tumors, and acute myeloid leukemia.The preclinical animal trials were conducted using humanized mast cell neoplasm models, representative in vitro and in vivo models for aggressive, mast cell-derived cancers, such as mast cell leukemia and mast cell sarcoma. Key findings of the mouse models found that HT-KIT:
  • Reduces KIT expression and induces apoptosis of neoplastic human mast cells
  • Inhibits tumor growth in humanized xenograft mast cell neoplasia models
  • Reduces liver infiltration of neoplastic mast cells
  • Reduces tumor growth in isograft models of mast cell neoplasia
  • Reduces signs of mast cell leukemia in an isograft model of mutant mast cell neoplasia
Listen to the Webcast


You are about to review presentations, reports and/or filings of Hoth Therapeutics, Inc., that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Hoth Therapeutics, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by Hoth Therapeutics, Inc.